Recent advances in the immunology of xenotransplantation

Immunologic Research

Volumn 16, Issue 3, 1997, Pages 273-297

  Takahashi, Takao ^a,b   Saadi, Soheyla ^a   Platt, Jeffrey L ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Departments of Surgery II   (Japan)

Author keywords

Accommodation; Acute vascular rejection; Complement; Endothelial cells; Hyperacute rejection; Xenoreactive antibodies; Xenotransplantation

Indexed keywords

ANTIBODY; COMPLEMENT;

GRAFT REJECTION; IMMUNE RESPONSE; NATURAL KILLER CELL; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TISSUE TRANSPLANTATION; XENOTRANSPLANTATION;

EID: 0030696244     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786395     Document Type: Review

References (165)

1. Evans RW, Orians CE, Ascher NL: The potential supply of organ donors: an assessment of the efficiency of organ procurement efforts in the United States. JAMA 1992;267:239-246.
2. Starzl TE, Fung J, Tzakis A, Todo S, Demetris AJ, Marino IR, Doyle H, Zeevi A, Warty V, Michaels M, Kusne S, Rudert WA, Trucco M: Baboon-to-human liver transplantation. Lancet 1993;341:65-71.
3. Platt JL: Xenotransplanting hepatocytes: the triumph of a cup half full. Nat Med 1997;3:26-27.
4. Rosengard BR, Adachi H, Ueda K, Hall TS, Hutchins GM, Herskowitz A, Borkon AM, Baumgartner WA, Reitz BA: Differences in the pathogenesis of first-set allograft rejection and acute xenograft rejection as determined by sequential morphologic analysis. J Heart Transpl 1986;5:263-266.
5. Jamieson SW: Xenograft hyperacute rejection: a new model. Transplantation 1974;17:533-534.
6. Perper RJ, Najarian JS: Experimental renal heterotransplantation. I. In widely divergent species. Transplantation 1966;4: 377-388.
7. Cooper DKC, Human PA, Lexer G, Rose AG, Rees J, Keraan M, Du Toit E: Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J Heart Transplant 1988; 7:238-246.
8. Collins BH, Cotterell AH, McCurry KR, Alvarado CG, Magee JC, Parker W, Platt JL: Hyperacute rejection of cardiac xenografts between primate species: evidence to support the significance of the α-Galactosyl determinant. J Immunol 1995;154: 5500-5510.
9. Roslin MS, Tranbaugh RE, Panza A, Coons MS, Kim Y-D, Chang T, Cunningham JN, Norin AJ: One- year monkey heart xenograft survival in cyclosporine-treated baboons. Transplantation 1992; 54:949-955.
10. Parker W, Yu PB, Holzknecht ZE, Lundberg-Swanson K, Buckley RH, Platt JL: Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B-cell lineage and development. J Clin Immunol 1997; in press.
11. Edwards J: Complement activation by xenogeneic red blood cells. Transplantation 1981;31: 226,227.
12. Miyagawa S, Hirose H, Shirakura R, Naka Y, Nakata S, Kawashima Y, Seya T, Matsumoto M, Uenaka A, Kitamura H: The mechanism of discordant xenograft rejection. Transplantation 1988;46:825-830.
13. Leventhal JR, Matas AJ, Sun LH, Reif S, Bolman RM III, Dalmasso AP, Platt JL: The immunopathology of cardiac xenograft rejection in the guinea pig to rat model. Transplantation 1993;56:1-8.
14. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR Jr, Bach FH, Dalmasso AP: Release of heparan sulfate from endothelial cells: implications for pathogenesis of hyperacute rejection. J Exp Med 1990;171:1363-1368.
15. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH: Immunopathology of hyperacute xenograft rejection in a swine-to- primate model. Transplantation 1991;52:214-220.
16. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL: Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992;140:1157-1166.
17. Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH: Transplantation of discordant xenografts: a review of progress. Immunol Today 1990;11:450-456.
18. Lawson JH, Daniels L, Platt JL: The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc 1997; 29:884-885.
19. Platt JL: Hyperacute Xenograft Rejection, New York, Springer- Verlag, 1995.
20. Lin SS, Platt JL: Immunologic barriers to xenotransplantation. J Heart Lung Transplant 1996; 15:547-555.
21. Saadi S, Ihrcke NS, Platt JL: Pathophysiology of xenograft rejection; in Lieberman R, Morris R (eds): Principles of Immunomodulatory Drug Development in Transplantation and Autoimmunity. New York, Raven, 1996, pp. 31-45.
22. Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M, Platt JL: Transplantation of discordant xenografts: a challenge revisited. Immunol Today 1996;17:373-378.
23. Calne RY: Organ transplantation beween widely disparate species. Transpl Proc 1970;2:550-556.
24. Chopek MW, Simmons RL, Platt JL: ABO incompatible renal transplantation: initial immunopathologic evaluation. Transpl Proc 1987;19:4553-4557.
25. Bannett AD, McAlack RF, Morris M, Chopek M, Platt JL: ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplant. Transpl Proc 1989;21:783-785.
26. Auchincloss H Jr: Xenogeneic transplantation. Transplantation 1988;46:1-20.
27. Egdahl RH, Good RA, Varco RL: Studies in homograft and heterograft survival. Surgery 1957;42:228-239.
28. Pierson RN, Winn HJ, Russell PS, Auchincloss H: Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J Exp Med 1989;170:991-996.
29. Kaufman DB, Platt JL, Rabe FL, Stock PG, Sutherland DER: The immunological basis of islet allograft primary non-function. J Exp Med 1990;172:291-302.
30. Winn HJ, Baldamus CA, Jooste SV, Russell PS: Acute destruction by humoral antibody of rat skin grafted to mice: The role of complement and polymorphonuclear leukocytes. J Exp Med 1973;137:893-910.
31. Baldamus CA, McKenzie IF, Winn HJ, Russell PS: Acute destruction by humoral antibody of rat skin grafted to mice. J Immunol 1973;110:1532-1541.
32. Jooste SV, Colvin RB, Winn HJ: The vascular bed as the primary target in the destruction of skin grafts by antiserum. J Exp Med 1981;154:1332-1341.
33. Giles GR, Boehmig HJ, Lilly J, Amemiya H, Takagi H, Coburg AJ, Hathaway WE, Wilson CB, Dixon FJ, Starzl TE: Mechanism and modification of rejection of heterografts between divergent species. Transpl Proc 1970;2:522-537.
34. Rose AG, Cooper DKC, Human PA, Reichenspurner H, Reichart B: Histopathology of hyperacute rejection of the heart: experimental and clinical observations in allografts and xenografts. J Heart Lung Transplant 1991;10:223-234.
35. Forbes RDC, Kuramochi T, Guttmann RD, Klassen J, Knaack J: A controlled sequential morphologic study of hyperacute cardiac allograft rejection in the rat. LabInv 1975;33:280-288.
36. Busch GJ, Martins ACP, Hollenberg NK, Wilson RE, Colman RW: A primate model of hyperacute renal allograft rejection. Am J Pathol 1975;79:31-56.
37. Colman RB, Habal M, Hollenberg NK, Birtch AG, Busch GJ: Hyperacute renal allograft rejection in the primate. Am J Pathol 1976;82:25-42.
38. Platt, J.L.: Xenotransplantation; in Wood, K (ed): Handbook of Transplant Immunology. Bucks, Medical & Scientific Publications, UK, 1995, pp. 259-299.
39. Platt JL, Bach FH: The barrier to Xenotransplantation. Transplantation 1991;52:937-947.
40. Perper RJ, Najarian JS: Experimental renal heterotransplantation. III. Passive transfer of transplantation immunity. Transplantation 1967;5:514-533.
41. Larsen, S, Starklint H: Histopathology of kidney xenograft rejetion; in Cooper DKC, Kemp E, Reemtsma K, White DJG (eds.): Xenotransplantation. The Transplantation of Organs and Tissues Between Species. New York, Springer-Verlag, 1991, pp. 181-206.
42. Bustos M: Platelet-endothelial cell interactions in a xenograft model. Trans Proc 1997;29:886.
43. Boyden SV: Natural antibodies and the immune response. Adv Immunol 1964;5:1-28.
44. Hammer C: Preformed natural antibodies (PNAB) and possibilities of modulation of hyperacute xenogeneic rejection (HXAR). Transplant Proc 1989;21:522-523.
45. Parker W, Platt JL: Xenoreactive human natural antibodies; in Peter JB, Schoenfeld Y (eds.): Autoantibodies. Amsterdam, Elsevier Science, 1996, pp. 846-851.
46. Parker W, Bruno D, Platt JL: Xenoreactive natural antibodies in the world of natural antibodies: Typical or Unique? Transplant Immunology 1995;3:181-191.
47. Platt JL, Turman MA, Noreen HJ, Fischel RJ, Bolman RM, Bach FH: An ELISA assay for xenoreactive natural antibodies. Transplantation 1990;49:1000-1001.
48. Parker W, Lundberg-Swanson KL, Holzknecht ZE, Lateef J, Washburn SA, Braedehoeft SJ, Platt JL: Isohemagglutinins and xenoreactive antibodies are members of a distinct family of natural antibodies. Hum Immunol 1996;45:94-104.
49. Gewurz H, Clark DS, Finstad J, Kelly WD, Varco RL, Good RA, Gabrielsen AE: Role of the complement system in graft rejections in experimental animals and man. Ann NY Acad Sci 1966;129:673-713.
50. Clark DS, Gewurz H, Good RA, Varco RL: Complement fixation during homograft rejection. Surg Forum 1964;15:144-146.
51. Kaplon RJ, Michler RE, Xu H, Kwiatkowski PA, Edwards NM, Platt JL: Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1994;59:1-6.
52. Platt JL, Lindman BJ, Geller RL, Noreen HJ, Swanson JL, Dalmasso AP, Bach FH: The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 1991;52:1037-1043.
53. Parker W, Bruno D, Holzknecht ZE, Platt JL: Xenoreactive natural antibodies: isolation and initial characterization. J Immunol 1994;153:3791-3803.
54. Yu PB, Holzknecht ZE, Bruno D, Parker W, Platt JL: Modulation of natural IgM binding and complement activation by natural IgG antibodies. J Immunol 1996; 157:5163-5168.
55. Magee JC, Collins BH, Harland RC, Lindman BJ, Bollinger RR, Frank MM, Platt JL: Immunoglobulin prevents complement mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96:2404-2412.
56. Good AH, Cooper DKC, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N, Lamontagne LR: Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992;24:559-562.
57. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC: Anti-pig IgM antibodies in human serum react predominantly with Galα(1,3)Gal epitopes. Proc Natl Acad Sci USA 1993;90:11,391-11,395.
58. Collins BH, Parker W, Platt JL: Characterization of porcine endothelial cell determinants recognized by human natural antibodies. Xenotransplantation 1994;1:36-46.
59. Neethling FA, Koren E, Ye Y, Richards SV, Kujundzic M, Oriol R, Cooper DKC: Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by α-galactosyl oligosaccharides. Transplantation 1994;57:959-963.
60. Galili U, Rachmilewitz EA, Peleg A, Flechner I: A unique natural human IgG antibody with anti-α- galactosyl specificity. J Exp Med 1984;160:1519-1531.
61. Galili U: Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993;14:480-482.
62. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA: Evolutionary relationship between the natural anti-Gal antibody and the Gal α1-3Gal epitope in primates. Proc Natl Acad Sci USA 1987; 84:1369-1373.
63. Sachs DH, Sablinski T: Tolerance across discordant xenogeneic barriers. Xenotransplantation 1995;2: 234-239.
64. Platt JL, Holzknecht ZE: Porcine platelet antigens recognized by human xenoreactive natural antibodies. Transplantation 1994; 57:327-335.
65. Cotterell AH, Alvarado CG, Logan JS, Platt JL: Variation in expression of porcine antigens recognized by human xenoreactive natural antibodies. Transplant Proc 1995;27:278,279.
66. Geller RL, Rubinstein P, Platt JL: Variation in expression of porcine xenogeneic antigens. Transplantation 1994;58:272-277.
67. Alvarado CG, Cotterell AH, McCurry KR, Collins BH, Magee JC, Berthold J, Logan JS, Platt JL: Variation in the level of xenoantigen expression in porcine organs. Transplantation 1995;59:1589-1596.
68. Holzknecht ZE, Platt JL: Identification of porcine endothelial cell membrane antigens recognized by human xenoreactive antibodies. J Immunol 1995;154:4565-4575.
69. Lampugnani MG, Resnati M, Dejana E, Marchisio PC: The role of integrins in the maintenance of endothelial monolayer integrity. J Cell Biol 1991;112:479-490.
70. Kornberg LJ, Earp HS, Turner CE, Prockop C, Juliano RL: Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of b1 integrins. Proc Natl Acad Sci USA 1991; 88:8392-8396.
71. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
72. Baumgartner HR, Tschopp TB, Meyer D: Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIIl/von Willebrand factor. Br J Haematol 1980;44:127-139.
73. Turitto VT, Weiss HJ, Zimmerman TS, Sussman II: Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood 1985;65:823-831.
74. Roth GJ: Platelets and blood vessels: The adhesion event. Immunol Today 1992;13:100-105.
75. Bannett AD, McAlack RF, Raja R, Baquero A, Morris M: Experiences with known ABO-mismatched renal transplants. Transplant Proc 1987;19:4543-4546.
76. Cooper DKC, Ye Y, Niekrasz M, Kehoe M, Martin M, Neethling FA, Kosanke S, DeBault LE, Worsley G, Zuhdi N, Oriol R, Romano E: Specific intravenous carbohydrate therapy: a new concept in inhibiting antibody- mediated rejection - experience with ABO-incompatible cardiac allografting in the baboon. Transplantation 1993;56:769-777.
77. Ye Y, Neethling FA, Niekrasz M, Koren E, Richards SV, Martin M, Kosanke S, Oriol R, Cooper DKC: Evidence that intravenously administered α-Galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15) and transplanted pig hearts. Transplantation 1994;58: 330-337.
78. Sandrin M, Vaughn H, Dabowski P, Henning M, McKenzie I: Molecular Characterization of the major pig xenoantigen: Galα(1,3) Gal. Transplant Proc 1994.
79. Strahan K, Gu F, Andersson L, Gustafsson K: Pig α 1,3 galactosyltransferase: sequence of a full length cDNA clone and chromosomal localisation of the corresponding gene. Transplant Proc 1995;27:245-248.
80. Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJW, Lonie AJ, Lyons I, Nottle MB, Cox T, Becker C, Peura AM, Wigley PL, Crawford RJ, Robins AJ, Pearse MJ, D'Apice AJF: The α-1,3-galactosyltransferase knockout mouse. Transplantation 1996;61:13-19.
81. Sandrin MS, Fodor WL, Mouhtouris E, Osman N, Cohney S, Rollins SA, Guilmette ER, Setter E, Squinto SP, McKenzie I: Enzymatic remodelling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995;1:1261-1267.
82. Sharma A, Okabe JF, Birch P, Platt JL, Logan JS: Reduction in the level of gal (α1,3) gal in transgenic mice and pigs by the expression of an α(1,2) fucosyltransferase. Proc Natl Acad Sci USA 1996;93:7190-7195.
83. Gewurtz H, Clark DS, Finstad J, Kelly WD, Varco RL: Role of the complement system in graft rejections in experimental animals and man. Ann NY Acad Sci 1966;129:673-713.
84. Pruitt SK, Kirk AD, Bollinger RR, Marsh HC Jr, Collins BH, Levin JL, Mault JR, Heinle JS, Ibrahim S, Rudolph AR, Baldwin WM III, Sanfilippo F: The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57:363-370.
85. Gewurz H, Clark DS, Cooper MD, Varco RL, Good RA: Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation 1967; 5:1296-1303.
86. Leventhal JR, Dalmasso AP, Cromwell JW, Platt JL, Manivel CJ, Bolman RM, Matas AJ: Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993;55:857-866.
87. Chartrand C, O'Regan S, Robitaille P, Pinto-Blonde M: Delayed rejection of cardiac xenografts in C6-deficient rabbits. Immunology 1979;38:245-248.
88. Brauer RB, Baldwin WM III, Daha MR, Pruitt SK, Sanfilippo F: Use of Co-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993;151:7240-7248.
89. Platt JL, Logan JS: The generation and use of transgenic animals for xenotransplantation; in Houdebine LM (ed.): Transgenic Animals: Generation and Use. Amsterdam, Harwood Academic Publishers gmbh, 1997, in press.
90. Lawson JH, Platt JL: Molecular barriers to xenotransplantation. Transplantation 1996;62:303-310.
91. Johnston P, Lim S, Wright L, White D: Hyperacute xenograft rejection takes place in the complete absence of antibodies but requires the presence of functional complement. Transplant Proc 1991;23:877-884.
92. Dalmasso AP, Platt JL: Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 1993;56:1171-1176.
93. Johnston PS, Wang M-W, Lim SML, Wright LJ, White DJG: Discordant xenograft rejection in an antibody-free model. Transplantation 1992;54:573-576.
94. Muller-Eberhard HJ: Molecular organization and function of the complement system. Annu Rev Biochem 1988;57:321-347.
95. Atkinson JP, Oglesby TJ, White D, Adams EA, Liszewski MK: Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 1991;86(Suppl 1):27-30.
96. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH: Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991;52:530-533.
97. Pangburn MK, Schreiber RD, Muller-Eberhard HJ: Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983;80:5430-5434.
98. Nicholson-Weller A, March JP, Rosenfeld SI, Austen F: Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983;80: 5066-5070.
99. Matsuo S, Ichida S, Takizawa H, Okada N, Baranyi L, Iguchi A, Morgan BP, Okada H: In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med 1994;180:1619-1627.
100. McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS, Platt JL: Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995;1:423-427.
101. Byrne GW, McCurry KR, Martin MJ, McClellan SM, Platt JL, Logan JS: Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement- mediated damage. Transplantation 1997;63:149-155.
102. Basta M, Kirshbom P, Frank MM, Fries LF: Mechanism of therapeutic effect on high-dose intravenous immunoglobulin - attenuation of acute, complement- dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974-1981.
103. Zhow XJ, Niesen N, Pawlowski I, Biesecker G, Andres G, Brentjens J, Milgrom F: Prolongation of survival of discordant kidney xenografts by C6 deficiency. Transplantation 1990;50:896-898.
104. Kroshus TJ, Rollins SA, Dalmasso AP, Elliott EA, Matis LA, Squinto SP, Bolman RM: Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995;60:1194-1202.
105. Diamond LE, McCurry KR, Oldham ER, McClellan SB, Martin MJ, Platt JL, Logan JS: Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996;61:1241-1249.
106. Saadi S, Platt JL: Transient perturbation of endothelial integrity induced by antibodies and complement. J Exp Med 1995; 181:21-31.
107. Wrenshall LE, Platt JL, Chopek MW, Fischel R, Matas AJ: ABO incompatible transplantation in pigtail macaque monkeys. Transplant Proc 1991;23:703-704.
108. Vercellotti GM, Platt JL, Bach FH, Dalmasso AP: Neutrophil adhesion to xenogeneic endothelium via iC3b. J Immunol 1991;146:730-734.
109. Platt JL, Dalmasso AP, Lindman BJ, Ihreke NS, Bach FH: The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur J Immunol 1991;21:2887-2890.
110. Inverardi L, Samaja M, Motterlini R, Mangili F, Bender JR, Pardi R: Early recognition of a discordant xenogeneic organ by human circulating lymphocytes. J Immunol 1992;149:1416-1423.
111. Lanier LL, Phillips JH: Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today 1996;17:86-91.
112. Collins BH, Chari RS, Magee JC, Harland RC, Lindman BJ, Logan JS, Bollinger RR, Meyers WC, Platt JL: Mechanisms of injury in porcine livers perfused with blood of humans with fulminant hepatic failure. Transplantation 1994;58:1162-1171.
113. Blakely ML, Van Der Werf WJ, Berndt MC, Dalmasso AP, Bach FH, Hancock WW: Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994;58:1059-1066.
114. Saadi S, Platt JL: Endothelial cell responses to complement activation; in Volanakis JE, Frank MM (eds.): The Human Complement System in Health and Disease. New York, Dekker, 1997, in press.
115. Platt JL: Mechanisms of tissue injury in hyperacute xenograft rejection. ASAIO J 1992;38:8-16.
116. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL: Role of heparan sulfate in immune system- blood vessel interactions. Immunol Today 1993;14:500-505.
117. Ihrcke NS, Platt JL: Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell surface molecules. J Cell Physiol 1996;168:625-637.
118. Stevens RB, Wang YL, Kaji H, Lloveras J, Dalmasso AB, Bach FH, Rubinstein P, Sutherland DER, Platt JL: Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival. Transplant Proc 1993;25:382.
119. Key NS, Platt JL, Vercellotti GM: Vascular endothelial cell proteoglycans are susceptible to cleavage by neutrophils. Arterioscler Thromb 1992;12:836-842.
120. Magee JC, Platt JL, Oldham KT, Guice KS: Oxidant stress increases suceptibility of porcine endothelial cells to injury by xenoreactive antibodies and complement. Transplant Proc 1994;26:1170.
121. van Mourik JA, von dem Borne AEGK, Giltay JG: Pathophysiological significance on integrin expression by vascular endothelial cells. Biochem Pharmacol 1990; 39:233-239.
122. Stelzner TJ, Weil JV, O'Brien RF: Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J Cell Physiol 1989;139:157-166.
123. Naito M, Hayashi T, Kuzuya M, Funaki C, Asai K, Kuzuya F: Vascular endothelial cell migration in vitro roles of cyclic nucleotides. calcium ion and cytoskeletal system. Artery 1989;17:21-31.
124. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ: Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989;264:7768-7771.
125. Hattori R, Hamilton KK, McEver RP, Sims PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989;264:9053-9060.
126. Hamilton KK, Hattori R, Esmon CT, Sims PJ: Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990;265:3809-3814.
127. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF: GMP-140, a platelet alpha- granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989;84:92-99.
128. Geng JG, Bevilacquu MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP: Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990;343:757-760.
129. Pinsky D, Oz M, Liao H, Brett J, Morris S, Morales M, Van Lookeren Campagne M, Karakurum M, Platt JL, Nowygrod R, Stem DM, Koga S: Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model. J Clin Invest 1993;92:2994-3002.
130. Saadi S, Ihrcke NS, Platt JL: Endothelial cell shape and hyperacute rejection. Transplant Proc 1994;26:1149.
131. Matas AJ, Sibley R, Mauer M, Sutherland DER, Simmons RL, Najarian JS: The value of needle renal allograft biopsy. Ann Surg 1983;197:226-237.
132. Zehr KJ, Herskowitz A, Lee PC, Kumar P, Gillinov AM, Baumgartner WA: Neutrophil adhesion and complement inhibition prolongs survival of cardiac xenografts in discordant species. Transplantation 1994;57:900-906.
133. Cotterell AH, Collins BH, Parker W, Harland RC, Platt JL: The humoral immune response in humans following cross-perfusion of porcine organs. Transplantation 1995;60:861-868.
134. Alexandre GPJ, Gianello P, Latinne D, et al.: Plasmapheresis and splenectomy in experimental renal xenotransplantation: in Hardy MA(ed.): Xenograft 25. New York, Elsevier, 1989, pp. 259-266.
135. Leventhal JR, John R, Fryer JP, Wilson JC, Derlich J, Remiszewski J, Dalmasso A, Matas A, Bolman R: Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption: results of in vitro and in vivo studies. Transplantation 1995;59:294-300.
136. Thompson C: Humanised pigs hearts boost xenotransplantation. Lancet 1995;346:766.
137. Lin SS, Platt JL: The role of immunoabsorption in xenotransplantation. 1997, submitted.
138. Paul LC, Claas FHJ, van Es LA, Kalff MW, de Graeff J: Accelerated rejection of a renal allograft associated with pretransplantation antibodies directed against donor antigens on endothelium and monocytes. N Engl J Med 1979;300:1258-1260.
139. Abbas AK, Corson JM, Carpenter CB, Galvanek EG, Merrill JP, Dammin GJ: Immunologic enhancement of rat renal allografts. Am J Pathol 1974;75:271-284.
140. Hasan R, van den Bogaerde JB, Wallwork J, White DJG: Evidence that long-term survival of concordant xenografts is achieved by inhibition of antispecies antibody production. Transplantation 1992;54:408-413.
141. Fujino Y, Kawamura T, Hullett DA, Sollinger HW: Evaluation of cyclosporine, mycophenolate mofetil, and brequinar sodium combination therapy on hamster- to-rat cardiac xenotransplantation. Transplantation 1994;57:41-46.
142. Saadi S, Holzkhecht RA, Patte CP, Stern DM, Platt JL: Complement- mediated regulation of tissue factor activity in endothelium. J Exp Med 1995;182:1807-1814.
143. Bennett AD, McAlack RF, Morris M, Chopek M, Platt JL: ABO incompatible renal transplantation: A qualitative analysis of native endothelial tissue ABO antigens after transplant. Transplant Proc 1989;21:783-785.
144. Palmer A, Welsh K, Gjorstrup P, Taube D, Bewick M, Thick M: Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989;1:10-12.
145. Ross CN, Gaskin G, Gregor- MacGregor S, Patel AA, Davey NJ, Leghler RI, Williams G, Rees AJ, Pusey CD: Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation 1993;55:785-789.
146. Ulfvin A, Backer AE, Clausen H, Hakomori S, Rydberg L, Samuelsson BE, Breimer ME: Expression of glyeolipid blood group antigens in single human kidneys: change in antigen expression of rejected ABO incompatible kidney grafts. Kidney Int 1993;44:1289-1297.
147. Bach FH, Ferran C, Hechenleitner P, Mark W, Koyamada N, Miyatake T, Winkler H, Badrichani A, Cardinas D, Hancock WH: Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997;3:196-204.
148. Dalmasso AP, He T, Benson BA: Human IgM xenoreactive antibodies can induce resistance of porcine endothelial cells to complement-mediated injury. Xenotransplantation 1996;3:54-62.
149. Busso N, Huet S, Nicodeme E, Hiernaux J, Hyafil F: Refractory period phenomenon in the induction of tissue factor expression on endothelial cells. Blood 1991;78: 2027-2035.
150. Shibata T, Cosio FG, Birmingham DJ: Complement activation induces the expression of decay-accelerating factor on human mesangial cells. J Immunol 1991;147:3901-3908.
151. Geller RL, Turman MA, Dalmasso AP, Platt JL: The natural immune barrier to xenotransplantation. J Am Soc Nephrol 1993;3:1189-1200.
152. Fryer J, Leventhal JR, Dalmasso A, Chen S, Simone PA, Goswitz JJ, Reinsmoen NJ, Matas AJ: Beyond hyperacute rejection. Transplantation 1995;59:171-176.
153. Ricordi C, Lacy PE, Sterbenz K, Davie JM: Low-temperature culture of human islets or in vivo treatment with L3T4 antibody produces a marked prolongation of islet human-to-mouse xenograft survival. Proc Natl Acad Sci USA 1987;84:8080-8084.
154. Marchetti P, Scharp DW, Finke EH, Swanson CJ, Olack BJ, Gerasimidi- Vazeou D, Giannarelli R, Navalesi R, Lacy PE: Prolonged survival of discordant porcine islet xenografts. Transplantation 1996;61:1100-1102.
155. Alter BJ, Bach FH: Cellular basis of the proliferative response of human T cells to mouse xenoantigens. J Exp Med 1990;191:333-338.
156. Irwin MJ, Heath WR, S herman LA: Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 1989;170:1091-1101.
157. Batten P, Heaton T, Fuller-Espie S, Lechler RI: Human anti-mouse xenorecognition. J Immunol 1995;155:1057-1065.
158. Moses RD, Winn HJ, Auchincloss H Jr: Multiple defects in cell surface molecule interactions across species differences are responsible for diminished xenogeneic T cell responses. Transplantation 1992;53:203-209.
159. Murray AG, Khodadoust MM, Pober JS, Bothwell ALM: Porcine aortic endothelial cells activate human T cells: Direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. Immunity 1994;1:57-63.
160. Kirk AD, Li RA, Kinch MS, Abernethy KA, Doyle C, Bollinger RR: The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness. Transplantation 1993;55:924-931.
161. Rollins SA, Kennedy SP, Chodera AJ, Elliott EA, Zavoico GB, Matis LA: Evidence that activation of human T cells by porcine endothelium involves direct recognition of porcine SLA and costimulation by porcine ligands for LFA-1 and CD2. Transplantation 1994;57:1709-1716.
162. Yamada K, Sachs DH, DerSimonian H: Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J Immunol 1995;155:5249-5256.
163. Wrenshall LE, Cerra FB, Singh RK, Platt JL: Heparan sulfate initiates signals in murine macrophages leading to divergent biological outcomes. J Immunol 1995;154:871-880.
164. Wrenshall LE, Cerra FB, Carlson A, Bach FH, Platt JL: Regulation of T lymphocyte responses by heparan sulfate. J Immunol 1991;147:455-459.
165. Wrenshall LE, Carlson A, Cerra FB, Platt JL: Modulation of cytolytic T- cell responses by heparan sulfate. Transplantation 1994;57:1087-1094.